- Home
- BDTX vs TORO Comparison
BDTX vs TORO Comparison
Compare BDTX & TORO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDTX | TORO |
|---|---|---|
| Founded | 2014 | 2022 |
| Country | United States | Cyprus |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.9M | 173.8M |
| IPO Year | 2020 | 2022 |
Fundamental Metrics
Financial Performance| Metric | BDTX | TORO |
|---|---|---|
| Price | $1.81 | $4.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $9.67 | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 27.9K |
| Earning Date | 05-08-2026 | 04-15-2026 |
| Dividend Yield | N/A | ★ 36.86% |
| EPS Growth | ★ 130.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $2.64 |
| 52 Week High | $4.94 | $8.50 |
Technical Indicators
Market Signals| Indicator | BDTX | TORO |
|---|---|---|
| Relative Strength Index (RSI) | 42.60 | 45.45 |
| Support Level | $1.60 | $4.87 |
| Resistance Level | $2.26 | $5.34 |
| Average True Range (ATR) | 0.13 | 0.19 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 19.42 | 27.78 |
Price Performance
Historical ComparisonAbout BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
About TORO Toro Corp.
Toro Corp is engaged in the acquisition, ownership, chartering, and operation of oceangoing tanker and LPG carrier vessels, providing seaborne transportation services for crude oil, refined petroleum products, and liquefied petroleum gas. The company operates through three segments: the Eco tanker segment, the Non-Eco tanker segment, and the LPG carrier segment. It generates the majority of its revenue from the LPG carrier segment.